BioStem Technologies (BSEM) AI Stock Analysis

• Market Cap: $64.95M
• Dividend Yield: N/A
• Average Volume (3M): 65.54K
• Price to Earnings (P/E): 3.9
• Beta (1Y): 1.90
• Revenue Growth: 11.78%
• EPS Growth: 37.44%
• Country: US
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.03
• Shares Outstanding: 16,338,436
• 10 Day Avg. Volume: 95,221
• 30 Day Avg. Volume: 65,540
• PEG Ratio: -0.02
• Price to Book (P/B): 5.54
• Price to Sales (P/S): 0.75
• P/FCF Ratio: 9.42
• Enterprise Value/Market Cap: 1.31
• Enterprise Value/Revenue: 0.28
• Enterprise Value/Gross Profit: 0.29
• Enterprise Value/Ebitda: 3.64
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 70 Outperform
• Price Target: $3.50 ▼(-33.96% Downside)

BioStem Technologies' overall stock score reflects strong financial performance and valuation, bolstered by strategic growth initiatives and consistent profitability. However, technical indicators suggest bearish momentum, which tempers the overall score. The company's low P/E ratio and strategic market expansions are significant positives, while recent revenue declines and technical weaknesses present challenges.

BioStem Technologies Business Overview & Revenue Model

Company Description

BioStem Technologies (BSEM) is a biotechnology company focused on advancing regenerative medicine and cellular therapy. The company specializes in developing innovative solutions for tissue repair and regeneration, leveraging its proprietary processes for the extraction and application of stem cells derived from various biological sources. BSEM operates primarily in the healthcare sector, offering a range of products and services that cater to both clinical and research applications, including stem cell storage, processing, and therapeutic treatments.

How the Company Makes Money

BioStem Technologies generates revenue through multiple key streams. Primarily, the company earns income from the processing and storage fees associated with stem cell collection services, where parents pay to store umbilical cord blood and tissue for potential future medical use. Additionally, BSEM monetizes its proprietary stem cell therapies and related products sold to healthcare providers and research institutions. Strategic partnerships with hospitals, clinics, and research organizations further enhance revenue opportunities through collaborative research and development projects. The company may also engage in licensing agreements for its technologies, providing another avenue for income generation.

BioStem Technologies Financial Statement Overview

Summary

BioStem Technologies demonstrates strong profitability and cash generation capabilities, with robust gross and net profit margins. However, recent declines in revenue growth and free cash flow growth pose potential risks. The company's low leverage is a positive factor, but the decrease in return on equity suggests a need for improved efficiency in utilizing equity capital.

Income Statement

BioStem Technologies shows strong gross profit margins consistently above 90%, indicating efficient cost management. However, recent revenue growth has declined by 7.58% in the TTM, which is a concern. The net profit margin remains healthy at 10.98%, reflecting profitability, but the decline in EBIT and EBITDA margins suggests potential operational challenges.

Balance Sheet

The company's debt-to-equity ratio is low at 0.11, indicating prudent leverage management. However, the return on equity has decreased from 78% to 65.93% in the TTM, suggesting reduced efficiency in generating returns from equity. The equity ratio is not provided, but the overall stability appears moderate.

Cash Flow

Operating cash flow and free cash flow are positive, with a high free cash flow to net income ratio of 0.98, indicating strong cash generation relative to profits. However, the free cash flow growth rate has declined by 3.84% in the TTM, which could impact future liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	307.26M	301.83M	16.69M	6.88M	4.34M	2.52M
Gross Profit	297.89M	287.86M	15.42M	5.99M	2.87M	1.25M
EBITDA	23.39M	31.49M	-7.55M	-6.52M	-602.00K	-2.25M
Net Income	26.26M	31.88M	-8.48M	-7.07M	-1.45M	-2.39M
Balance Sheet
Total Assets	112.61M	140.55M	14.56M	3.47M	2.67M	2.67M
Cash, Cash Equivalents and Short-Term Investments	30.84M	22.83M	239.41K	772.14K	340.33K	100.70K
Total Debt	3.59M	4.50M	4.77M	5.21M	4.83M	5.63M
Total Liabilities	64.52M	99.67M	15.90M	7.42M	8.47M	8.30M
Stockholders Equity	48.09M	40.88M	-1.34M	-4.08M	-5.96M	-5.80M
Cash Flow
Free Cash Flow	26.36M	24.05M	-3.60M	-2.11M	-152.29K	-585.25K
Operating Cash Flow	27.11M	24.48M	-3.50M	-1.64M	-109.44K	-581.57K
Investing Cash Flow	-2.00M	-1.68M	-210.33K	-469.48K	-7.85K	-3.69K
Financing Cash Flow	-840.43K	-206.78K	3.18M	597.71K	357.42K	541.52K

BioStem Technologies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BSEM, the sentiment is Negative. The current price of 5.3 is above the 20-day moving average (MA) of 4.33, above the 50-day MA of 4.71, and below the 200-day MA of 9.89, indicating a bearish trend. The MACD of -0.34 indicates Positive momentum. The RSI at 33.14 is Neutral, neither overbought nor oversold. The STOCH value of 22.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BSEM.

BioStem Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BSEM	70 Outperform	$64.95M	3.95	55.46%	―	11.78%	37.44%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IPHA	49 Neutral	$167.09M	―	-271.32%	―	-75.77%	-31.24%
VYGR	46 Neutral	$218.51M	―	-46.09%	―	-80.88%	-388.61%
DMAC	42 Neutral	$308.82M	―	-64.12%	―	―	-29.73%
BDTX	33 Underperform	$228.47M	11.05	19.23%	―	―	―

BioStem Technologies Corporate Events

BioStem Technologies Q3 Earnings Call Highlights Resilience

BioStem Technologies recently held its third-quarter earnings call, showcasing a strategic growth trajectory despite facing some financial challenges. The overall sentiment was one of resilience and optimism, as the company highlighted its ability to increase product volume and maintain strong gross margins, even as it navigated competitive pricing pressures and strategic investments that impacted revenue and cash balances.

BioStem Technologies Reports Q3 2025 Financial Results

BioStem Technologies, Inc. is a MedTech company specializing in the development, manufacturing, and commercialization of placental-derived products for advanced wound care, leveraging its proprietary BioREtain® processing method. The company operates within the regenerative medicine sector and is recognized for its innovative approach to harnessing the natural properties of perinatal tissue.

BioStem Technologies’ Promising Clinical Trial for Venous Leg Ulcers: A Potential Game-Changer

BioStem Technologies is conducting a clinical study titled A Prospective, Multicenter, Randomized, Controlled Trial of Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC. The study aims to determine if the application of BioREtain® Amnion Chorion (BR-AC) can enhance healing in patients with non-healing venous leg ulcers compared to standard care alone. This research is significant as it could offer a new treatment avenue for a condition that affects many patients worldwide.

BioStem Technologies’ Promising Study on Diabetic Foot Ulcers: A Potential Game-Changer

BioStem Technologies is conducting a clinical study titled A Prospective, Multicenter, Randomized, Controlled Trial of Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-AM. The study aims to evaluate the safety and efficacy of the BioREtain® Amniotic Membrane (BR-AM) in conjunction with standard care compared to standard care alone for treating diabetic foot ulcers. This research is significant as it could offer a new treatment option for a challenging condition.

BioStem Technologies’ Earnings Call: Mixed Sentiment Amid Growth Plans

BioStem Technologies’ recent earnings call presented a mixed sentiment, reflecting both optimism and challenges. While the company continues to demonstrate operational and clinical advancements with a positive EBITDA and strategic growth initiatives, it faces significant hurdles due to a notable revenue decline and uncertainties in reimbursement. The sentiment remains balanced, with strong financial metrics and future potential weighed against current market and competitive pressures.